Finding Value in an Underappreciated Cancer Drug cover art

Finding Value in an Underappreciated Cancer Drug

Finding Value in an Underappreciated Cancer Drug

Listen for free

View show details

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary

For patients with ROS1-positive lung cancer, treatment must contend not only with tumors in the lung but also the risk of it spreading to the brain and the eventual emergence of drug resistance. Nuvation Bio is addressing those challenges with Ibtrozi, an oral ROS1 inhibitor acquired through its purchase of AnHeart Therapeutics and developed to act in the central nervous system. David Hung, CEO of Nuvation Bio, discuses the company’s success in bringing the therapy to patients, its efforts to expand its use to earlier in the course of the disease, and how that first commercial product sets a foundation for a longer-term oncology business.

No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.